Short Time to Market and Forward Planning Will Enable Cell Therapies to Deliver R&D Pipeline Value.
autologous cell therapy
cost of development
cost of goods
oncology cell therapy
pipeline value
Journal
Human gene therapy
ISSN: 1557-7422
Titre abrégé: Hum Gene Ther
Pays: United States
ID NLM: 9008950
Informations de publication
Date de publication:
May 2021
May 2021
Historique:
pubmed:
8
10
2020
medline:
1
2
2022
entrez:
7
10
2020
Statut:
ppublish
Résumé
There is considerable industry excitement about the curative potential of cell and gene therapies, but significant challenges remain in designing cost-effective treatments that are accessible globally. We have taken a modeling-based approach to define the cost and value drivers for cell therapy assets during pharmaceutical drug development. We have created a model development program for a lentiviral modified
Identifiants
pubmed: 33023309
doi: 10.1089/hum.2020.212
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM